share_log

恒瑞医药收到美国FDA关于注射用卡瑞利珠单抗的完整回复信的公告

Hengrui Pharmaceutical received a complete response letter from the US FDA regarding injectable carelizumab

Sensex a share ·  May 18

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.